



Participant name:	
Hospital ID:	
CHI/Date of Birth:	

**GREAT-2 GRemubamab ErAdication Trial**

Sponsor University of Dundee-NHS Tayside  
Chief Investigator Professor James Chalmers  
IRAS number 1005993

Principal Investigator	
Contact number	
Contact email	

**Visit 4 – Treatment phase  
to be filed in medical notes as source data**

Date of visit:  Participant trial ID

Please tick to indicate the following has been completed:

Confirmed participant's identity	<input type="checkbox"/>
Concomitant medications have been reviewed	<input type="checkbox"/>
Adverse events have been reviewed	<input type="checkbox"/>
Exacerbations have been reviewed	<input type="checkbox"/>

Questionnaires:

Quality of Life-Bronchiectasis Questionnaire	<input type="checkbox"/>
Bronchiectasis Impact Measure Questionnaire	<input type="checkbox"/>

Research samples:

Research blood samples	<input type="checkbox"/>
Sputum sample	<input type="checkbox"/>

**Vital signs**

Please enter the results of the following assessments:

Blood pressure	<input type="text"/>	mmHg	Pulse	<input type="text"/>	bpm
Oxygen saturation (room air)	<input type="text"/>	%	Tympanic temperature	<input type="text"/>	°C

The following must be filed in the participant's medical notes:

- Changes to concomitant medications since last visit
- Any adverse events since last visit
- Any pulmonary exacerbations since last visit
- Any other notable findings and actions taken
- If the participant was withdrawn from the trial at this visit, document reason



Participant name:	
Hospital ID:	
CHI/Date of Birth:	

Visit has been carried out as per protocol

Signature:	
Name:	
Job title:	
Date:	